Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
3.930
-0.160 (-3.91%)
Oct 21, 2025, 3:31 PM EDT - Market open
Clearside Biomedical Revenue
Clearside Biomedical had revenue of $492.00K in the quarter ending June 30, 2025, with 446.67% growth. This brings the company's revenue in the last twelve months to $4.17M, down -44.63% year-over-year. In the year 2024, Clearside Biomedical had annual revenue of $1.66M, down -79.77%.
Revenue (ttm)
$4.17M
Revenue Growth
-44.63%
P/S Ratio
5.00
Revenue / Employee
$130,188
Employees
32
Market Cap
20.57M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.66M | -6.56M | -79.77% |
Dec 31, 2023 | 8.23M | 6.90M | 519.89% |
Dec 31, 2022 | 1.33M | -28.25M | -95.51% |
Dec 31, 2021 | 29.58M | 21.68M | 274.65% |
Dec 31, 2020 | 7.89M | 5.72M | 263.28% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CLSD News
- 2 months ago - Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress - GlobeNewsWire
- 3 months ago - Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - GlobeNewsWire
- 3 months ago - Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - GlobeNewsWire
- 4 months ago - Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - GlobeNewsWire
- 5 months ago - Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum - GlobeNewsWire
- 5 months ago - Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - GlobeNewsWire
- 5 months ago - Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025 - GlobeNewsWire